E-LIB Suche - Ergebnisse für: Josep Tabernero

1

Tislelizumab plus chemotherapy versus placebo plus chemothe..:

Qiu, Miao-Zhen ; Oh, Do-Youn ; Kato, Ken...
BMJ. , 2024

2

Modified FOLFOX6 plus bevacizumab with and without nivoluma..:

Lenz, Heinz-Josef ; Parikh, Aparna ; Spigel, David R...
Journal for ImmunoTherapy of Cancer. 12 (2024) 3 - p. e008409 , 2024

Link: https://doi.org/10.1136/..

3

Cetuximab as a Key Partner in Personalized Targeted Therapy..:

Saoudi González, Nadia ; Ros, Javier ; Baraibar, Iosune...
Cancers. 16 (2024) 2 - p. 412 , 2024

Link: https://doi.org/10.3390/..

4

CEA-CD3 bispecific antibody cibisatamab with or without ate..:

Segal, Neil H. ; Melero, Ignacio ; Moreno, Victor...
Nature Communications. 15 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

5

A Randomized Phase III Study of Arfolitixorin versus Leucov..:

Tabernero, Josep ; Yoshino, Takayuki ; Stintzing, Sebastian...
Cancer Research Communications. 4 (2024) 1 - p. 28-37 , 2024

Link: https://doi.org/10.1158/..

6

Mo1250 PATHOLOGICAL COMPLETE RESPONSE (PCR) TO DURVALUMAB P..:

Molena, Daniela ; Janjigian, Yelena ; Al-Batran, Salah-Eddin...
Gastroenterology. 166 (2024) 5 - p. S-996 , 2024

Link: https://doi.org/10.1016/..

7

Current and Emerging Treatment Paradigms in Colorectal Canc..:

Salva de Torres, Clara ; Baraibar, Iosune ; Saoudi González, Nadia...
International Journal of Molecular Sciences. 25 (2024) 13 - p. 6967 , 2024

Link: https://doi.org/10.3390/..

8

UNCAN.eu: Toward a European Federated Cancer Research Data ..:

Boutros, Michael ; Baumann, Michael ; Bigas, Anna...
Cancer Discovery. 14 (2024) 1 - p. 30-35 , 2024

Link: https://doi.org/10.1158/..

9

Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor A..:

Steeghs, Neeltje ; Gomez-Roca, Carlos ; Rohrberg, Kristoffer S....
Clinical Cancer Research. , 2024

Link: https://doi.org/10.1158/..

10

Efficacy of immune checkpoint inhibitors for metastatic col..:

Cohen, Romain ; Raeisi, Morteza ; Chibaudel, Benoist...
European Journal of Cancer. 199 (2024) - p. 113537 , 2024

Link: https://doi.org/10.1016/..

11

Drug Cost Avoidance Resulting from Participation in Clinica..:

Carreras, Maria-Josep ; Renedo-Miró, Berta ; Valdivia, Carolina...
Cancers. 16 (2024) 8 - p. 1529 , 2024

Link: https://doi.org/10.3390/..

12

SEAMARK: phase II study of first-line encorafenib and cetux..:

Elez, Elena ; Kopetz, Scott ; Tabernero, Josep...
Future Oncology. 20 (2024) 11 - p. 653-663 , 2024

Link: https://doi.org/10.2217/..

13

Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Admin..:

Bokemeyer, Carsten ; Ciardiello, Fortunato ; Dubreuil, Olivier...
Future Oncology. 20 (2024) 7 - p. 393-407 , 2024

Link: https://doi.org/10.2217/..

14

Safety profile of pembrolizumab monotherapy based on an agg..:

Brahmer, Julie R. ; Long, Georgina V. ; Hamid, Omid...
European Journal of Cancer. 199 (2024) - p. 113530 , 2024

Link: https://doi.org/10.1016/..

15

Prognostic value of liver metastases in colorectal cancer t..:

Cohen, Romain ; Raeisi, Morteza ; Chibaudel, Benoist...
European Journal of Cancer. 207 (2024) - p. 114160 , 2024

Link: https://doi.org/10.1016/..